Literature DB >> 29725799

The timeliness of patients reporting the side effects of chemotherapy.

Ian Olver1,2, Mariko Carey3,4,5, Allison Boyes3,4,5, Alix Hall4,5, Natasha Noble3,4,5, Jamie Bryant3,4,5, Justin Walsh3,4,5, Rob Sanson-Fisher3,4,5.   

Abstract

PURPOSE: To explore the actions cancer patients reported they would take in response to a range of common side effects of chemotherapy and whether these were considered appropriate based on current guidelines and evidence; and to explore the sociodemographic and cancer-related variables associated with patients selecting the appropriate action (immediate medical attention or reporting) for two potentially life-threatening side effects: fever, and unusual bleeding and bruising.
METHODS: Four hundred thirty-six medical oncology and haematology patients receiving chemotherapy completed two surveys to provide demographic, disease and treatment characteristics, and details on how they would respond if they experienced a range of specified side effects of chemotherapy (for example, nausea and vomiting, fatigue, and skin rash or nail changes). The proportion of patients reporting the appropriate action for each side effect was calculated. Multiple logistic regressions examined the patient demographic and cancer characteristics associated with selecting the appropriate action (seeking immediate medical attention) for two potentially life-threatening side effects of chemotherapy: high fever of 38 °C or more, and unusual bleeding or bruising.
RESULTS: Two thirds of patients indicated that they would seek immediate medical attention for high fever (67%), but only 41% would seek immediate attention for bleeding or bruising. Cancer type and time since diagnosis were significantly associated with patients indicating that they would seek immediate medical attention for high fever; while time since diagnosis was the only variable significantly associated with patients reporting that they would seek immediate medical attention for unusual bleeding or bruising. For chronic side effects, like skin rash or nail changes, and tingling or numbness, which usually do not require urgent reporting, only between 12 and 16% would report them immediately. A significant proportion of patients reported that they would "do nothing" about fatigue or tiredness (24%). By comparison, less than 10% patients reported that they would do nothing for the other side effects investigated.
CONCLUSIONS: Tools need to be created so that patients better understand the side effects after being treated with chemotherapy and what action they should take.

Entities:  

Keywords:  Chemotherapy; Quality of life; Self-reporting; Side effects; Timeliness

Mesh:

Year:  2018        PMID: 29725799     DOI: 10.1007/s00520-018-4225-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  26 in total

1.  Adverse drug reactions in current antihypertensive therapy: a general practice survey of 2586 patients in Norway.

Authors:  H Olsen; T Klemetsrud; H P Stokke; S Tretli; A Westheim
Journal:  Blood Press       Date:  1999       Impact factor: 2.835

2.  Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter?

Authors:  Annemarie Coolbrandt; Koen Van den Heede; Ellen Vanhove; Ann De Bom; Koen Milisen; Hans Wildiers
Journal:  Eur J Oncol Nurs       Date:  2010-08-03       Impact factor: 2.398

3.  Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults.

Authors:  M M Bergmann; T Byers; D S Freedman; A Mokdad
Journal:  Am J Epidemiol       Date:  1998-05-15       Impact factor: 4.897

4.  Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of life and associated supportive care: a cross-sectional survey.

Authors:  Richard Wagland; Alison Richardson; Sean Ewings; Jo Armes; Elaine Lennan; Matthew Hankins; Peter Griffiths
Journal:  Support Care Cancer       Date:  2016-07-27       Impact factor: 3.603

Review 5.  Men and health help-seeking behaviour: literature review.

Authors:  Paul M Galdas; Francine Cheater; Paul Marshall
Journal:  J Adv Nurs       Date:  2005-03       Impact factor: 3.187

6.  Chemotherapy dose intensity reductions due to adverse drug reactions in an oncology outpatient setting.

Authors:  Pilar Llopis-Salvia; Gema Sarrio-Montes; Paula Garcia-Llopis; Adria Bargues-Ruiz
Journal:  J Oncol Pharm Pract       Date:  2009-12-16       Impact factor: 1.809

Review 7.  Patient characteristics as predictors of primary health care preferences: a systematic literature analysis.

Authors:  Hans Peter Jung; Cor Baerveldt; Frede Olesen; Richard Grol; Michel Wensing
Journal:  Health Expect       Date:  2003-06       Impact factor: 3.377

Review 8.  Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.

Authors:  Christine Herbst; Frauke Naumann; Eva-Brigitta Kruse; Ina Monsef; Julia Bohlius; Holger Schulz; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

9.  Time to antibiotics and outcomes in cancer patients with febrile neutropenia.

Authors:  Thomas Perron; Mohamed Emara; Shahid Ahmed
Journal:  BMC Health Serv Res       Date:  2014-04-10       Impact factor: 2.655

10.  Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cancer.

Authors:  Ann Langius-Eklöf; Marie-Therése Crafoord; Mats Christiansen; Maria Fjell; Kay Sundberg
Journal:  BMC Cancer       Date:  2017-07-04       Impact factor: 4.430

View more
  5 in total

1.  "It's a part of the patient": The experiences of patients with cancer undergoing home-based chemotherapy from patients' and nurses' perspectives.

Authors:  Hyoeun Jang; Sanghee Kim; DaeEun Kim; Mehee Park; Sunemee Rhue; Changmin Lee; Seulgee Kim; Byungmun Kang; Haeri Lee
Journal:  Asia Pac J Oncol Nurs       Date:  2022-04-22

2.  Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.

Authors:  Yinan Ding; Rui Yang; Weiping Yu; Chunmei Hu; Zhiyuan Zhang; Dongfang Liu; Yanli An; Xihui Wang; Chen He; Peidang Liu; Qiusha Tang; Daozhen Chen
Journal:  J Nanobiotechnology       Date:  2021-05-19       Impact factor: 10.435

3.  Implementation of the Symptom Navi © Programme for cancer patients in the Swiss outpatient setting: a study protocol for a cluster randomised pilot study (Symptom Navi© Pilot Study).

Authors:  Marika Bana; Karin Ribi; Susanne Kropf-Staub; Sabin Zürcher-Florin; Ernst Näf; Tanja Manser; Lukas Bütikofer; Felix Rintelen; Solange Peters; Manuela Eicher
Journal:  BMJ Open       Date:  2019-07-09       Impact factor: 2.692

4.  pH-Triggered Drug Release Controlled by Poly(Styrene Sulfonate) Growth Hollow Mesoporous Silica Nanoparticles.

Authors:  Fajar R Wibowo; Ozi A Saputra; Witri W Lestari; Mamoru Koketsu; Rino R Mukti; Ronny Martien
Journal:  ACS Omega       Date:  2020-02-20

Review 5.  Polymeric Systems for Cancer Immunotherapy: A Review.

Authors:  Thai Minh Duy Le; A-Rum Yoon; Thavasyappan Thambi; Chae-Ok Yun
Journal:  Front Immunol       Date:  2022-02-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.